January 2005 in “Urology” Alfuzosin reduces short-term surgery need after catheter removal, but long-term benefits are unclear; combination therapy may help prevent urinary issues.
April 2017 in “The Journal of urology/The journal of urology” 5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
August 2002 in “Inpharma Weekly”
30 citations
,
July 2001 in “BJUI” Combination therapy improves urinary flow and reduces residual urine, but needs better stent design.
April 2022 in “Reactions Weekly” 111 citations
,
June 2015 in “Age and Ageing” Dutasteride, fesoterodine, and finasteride are beneficial for older patients, while most other drugs should be used cautiously or avoided.
March 2014 in “Annals of Internal Medicine” Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
3 citations
,
January 2019 in “Therapeutic advances in urology” WS PRO 160 I 120 mg effectively treats urinary symptoms from BPH with good safety and tolerability.
February 2006 in “Inpharma Weekly” 97 citations
,
May 2004 in “British Journal of Urology” Dual therapy with specific medications can help manage male urinary symptoms and reduce side effects.
December 2013 in “Urology reports (St - Petersburg)” Sonirid Duo effectively treats benign prostatic hyperplasia.
June 2008 in “Drugs & therapy perspectives” Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
1 citations
,
November 2015 in “Cochrane library” 5-alpha-reductase inhibitors help treat urinary symptoms from an enlarged prostate.
September 2004 in “Inpharma Weekly” 6 citations
,
June 2022 in “Journal of Clinical Medicine” Tamsulosin with Serenoa repens is as effective as with 5-alpha-reductase inhibitors but causes fewer side effects.
January 2022 in “Drugs of Today”
10 citations
,
February 2009 in “European urology. Supplement” Treatment for benign prostatic hyperplasia involves drugs that either quickly relieve symptoms or reduce prostate size, with a combination offering more benefits but more side effects.
November 2013 in “The Journal of Urology”
September 2022 in “PubMed” Entadfi, a mix of finasteride and tadalafil, is used for BPH.
June 2011 in “British Journal of Urology” Regulatory challenges make developing combination therapies in urology difficult and costly.
2 citations
,
November 2019 in “Current Geriatrics Reports” Tailored treatment is crucial for elderly men with BPH due to potential risks and benefits of medications.
July 2025 in “International Journal of Health and Medicine” Tamsulosin and solifenacin together effectively reduce symptoms in BPH patients.
306 citations
,
August 2011 in “Journal of cachexia, sarcopenia and muscle” Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.
January 2019 in “Nihon Yakuri Gakkai nenkai yoshishu” Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.
May 2022 in “Reactions Weekly” December 2024 in “Reactions Weekly” December 2023 in “Reactions weekly” November 2014 in “Reactions Weekly”